Lima PB, Dias JAF, Cassiano DP, et al. - In this 90-day, prospective, randomized, single-blinded, two-arm, parallel-group comparative study, researchers sought to compare the effectiveness and tolerability of topical 0.2% Thiamidol (isobutylamido thiazolyl resorcinol) vs 4% hydroquinone for facial melasma. From September to November 2020, 50 women with facial melasma took part in a randomized, evaluator‐blinded, controlled study. Study participants were randomly assigned to apply a double layer of 0.2% Thiamidol twice a day or 4% hydroquinone cream at bedtime, for 90 days. The improvement in melasma achieved with 0.2% Thiamidol cream was not different from that achieved with 4% hydroquinone cream. Thiamidol may be a viable option for melasma patients who have had poor tolerability or treatment failure with hydroquinone.